Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-876-8191
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$230,000.00
Profitability
Miscellaneous
Employees61
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences Inc (NASDAQ:GNCA) announced its quarterly earnings data on Tuesday, April, 30th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.06. View Genocea Biosciences' Earnings History.
When is Genocea Biosciences' next earnings date?
What price target have analysts set for GNCA?
2 Wall Street analysts have issued twelve-month price targets for Genocea Biosciences' shares. Their predictions range from $5.75 to $5.75. On average, they anticipate Genocea Biosciences' share price to reach $5.75 in the next year. This suggests a possible upside of 727.5% from the stock's current price. View Analyst Price Targets for Genocea Biosciences.
What is the consensus analysts' recommendation for Genocea Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genocea Biosciences.
What are Wall Street analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (5/1/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, GEN-009. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (11/1/2018)
Has Genocea Biosciences been receiving favorable news coverage?
Media headlines about GNCA stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genocea Biosciences earned a news impact score of -1.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), Harpoon Therapeutics (HARP), Sutro Biopharma (STRO), Eiger Biopharmaceuticals (EIGR), Solid Biosciences (SLDB), AVITA MED LTD/S (AVMXY), ADMA Biologics (ADMA), Gamida Cell (GMDA), Compugen (CGEN), La Jolla Pharmaceutical (LJPC), Jounce Therapeutics (JNCE), Neon Therapeutics (NTGN), Novavax (NVAX) and Erytech Pharma (ERYP).
What other stocks do shareholders of Genocea Biosciences own?
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 50)
- Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 47)
- Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 74)
- Mr. Michael Alfieri, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 54)
- Ms. Pamela Carroll, Sr. VP of Immun-Oncology (Age 55)
Who are Genocea Biosciences' major shareholders?
Genocea Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (31.10%), BVF Inc. IL (6.96%), Vivo Capital LLC (6.95%), Fosun International Ltd (0.51%), Renaissance Technologies LLC (0.38%) and HighTower Advisors LLC (0.31%). Company insiders that own Genocea Biosciences stock include George Siber, Jonathan Poole, Michael Alfieri, Peter W Sonsini and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.
Which major investors are selling Genocea Biosciences stock?
Which major investors are buying Genocea Biosciences stock?
GNCA stock was purchased by a variety of institutional investors in the last quarter, including NEA Management Company LLC, BVF Inc. IL, HighTower Advisors LLC, Renaissance Technologies LLC and Fosun International Ltd. Company insiders that have bought Genocea Biosciences stock in the last two years include George Siber, Michael Alfieri, Peter W Sonsini and William D Clark. View Insider Buying and Selling for Genocea Biosciences.
How do I buy shares of Genocea Biosciences?
Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of GNCA stock can currently be purchased for approximately $0.6949.
How big of a company is Genocea Biosciences?
Genocea Biosciences has a market capitalization of $78.11 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Genocea Biosciences employs 61 workers across the globe.
What is Genocea Biosciences' official website?
How can I contact Genocea Biosciences?
Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]
MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
